{"classes":[{"categories":[{"measurements":[{"comment":"Here 'NA' indicates that the upper limit of 95% CI was not estimated due to lesser number of events.","groupId":"OG000","lowerLimit":"46.42","upperLimit":"NA","value":"54.87"},{"groupId":"OG001","lowerLimit":"18.56","upperLimit":"23.49","value":"21.22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"602"}],"units":"Participants"}],"description":"Time to subsequent therapy was defined as the time (in months) interval from the date of randomization to the date of initiation of subsequent therapy for prostate cancer.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received abiraterone acetate tablet at a total dose of 1000 milligram (mg) plus 5 mg capsule of prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) was administered.","id":"OG000","title":"Abiraterone Acetate+Prednisone+ADT"},{"description":"Participants received placebo matched to abiraterone acetate plus prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of ADT was administered.","id":"OG001","title":"Placebo + ADT"}],"paramType":"MEDIAN","populationDescription":"ITT analysis set included all subjects randomized into the study and who were classified according to their assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 66 months","title":"Time to Subsequent Therapy for Prostate Cancer","type":"SECONDARY","unitOfMeasure":"Months"}